VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the antitumor activity (in terms of overall
response rate - ORR - i.e. sum of complete and partial responses)of bortezomib in pretreated
MALT lymphomas with one prior sistemic therapy regimen
Phase:
Phase 2
Details
Lead Sponsor:
International Extranodal Lymphoma Study Group (IELSG)